In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) ...

Are you searching for effective medications to treat 'Alpha-1 Antitrypsin Deficiency'? This comprehensive guide provides the latest information on medications-both generic and branded-that are ...

In a previous study, the fecal biomarkers calprotectin and α1-antitrypsin (α1 ... 20, 21 First-line treatment with corticosteroids at a dose of 1–2 mg/kg/d was initiated in all patients ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

Quantification of stool alpha-1 Antitrypsin (sAAT) excretion is established for estimation of enteric protein loss and assessment of disease activity. This study is to access the feasibility of ...

Korro Bio (KRRO) announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025Alvelestat, for ...

Owing to the latest portfolio reorganization, Intellia has decided to stop the development of its in vivo gene insertion candidate, NTLA-3001, for the treatment of alpha-1 antitrypsin deficiency ...